Prothena Corporation plc (NASDAQ:PRTA)’s traded shares stood at 0.48 million during the last session, with the company’s beta value hitting 0.07. At the close of trading, the stock’s price was $15.14, to imply a decrease of -3.81% or -$0.6 in intraday trading. The PRTA share’s 52-week high remains $41.54, putting it -174.37% down since that peak but still an impressive 22.72% since price per share fell to its 52-week low of $11.70. The company has a valuation of $814.66M, with an average of 0.95 million shares in intraday trading volume over the past 10 days and average of 618.13K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Prothena Corporation plc (PRTA), translating to a mean rating of 1.40. Of 15 analyst(s) looking at the stock, 1 analyst(s) give PRTA a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 11 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -1.04.
Prothena Corporation plc (NASDAQ:PRTA) trade information
After registering a -3.81% downside in the last session, Prothena Corporation plc (PRTA) has traded red over the past five days. The 5-day price performance for the stock is -5.43%, and -2.82% over 30 days. With these gigs, the year-to-date price performance is -58.34%. Short interest in Prothena Corporation plc (NASDAQ:PRTA) saw shorts transact 8.06 million shares and set a 17.35 days time to cover.
The extremes give us $24 and $62 for target low and target high price respectively. As such, PRTA has been trading -309.51% off suggested target high and -58.52% from its likely low.
Prothena Corporation plc (PRTA) estimates and forecasts
Looking at statistics comparing Prothena Corporation plc share performance against respective industry, we note that the company has outperformed competitors. Prothena Corporation plc (PRTA) shares are -26.65% down over the last 6 months, with its year-to-date growth rate higher than industry average at 18.84% against 16.60%. The rating firms project that company’s revenue will grow 53.83% compared to the previous financial year.
Revenue forecast for the current quarter as set by 9 analysts is 7.53M. Meanwhile, for the current quarter, a total of 3 analyst(s) estimate revenue growth to 333.33k.Earnings reports from the last fiscal year show that sales brought in 316k and 50k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 2,283.93% before jumping 566.66% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 6.83% for the past 5-year period. While 2024 is set for a 19.77% return in earnings, projections for the next 5 years are at 34.07% annually.
PRTA Dividends
Prothena Corporation plc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Prothena Corporation plc (NASDAQ:PRTA)’s Major holders
Prothena Corporation plc insiders hold 13.46% of total outstanding shares, with institutional holders owning 96.97% of the shares at 112.05% float percentage. In total, 96.97% institutions holds shares in the company, led by ECOR1 CAPITAL, LLC. As of 2024-06-30, the company held over 11.58 million shares (or 21.5666% of shares), all amounting to roughly $239.1 million.
The next major institution holding the largest number of shares is FMR LLC with 8.07 million shares, or about 15.016% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $166.48 million.
